Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

APAiyana ParkerMDMaria DolaherWLWon‐Ho Lee

Discussion

Loading...

Member takes

Overview

Single-cell RNA sequencing reveals links between CAR T cell toxicity and response rates in multiple myeloma, suggesting crucial targets for earlier detection and therapeutic optimization.

Key Points

  • Elevated CAR+ T cell frequency links to neurotoxicities in cilta-cel therapy and raises concerns about treatment viability, underscoring the role of immune profile monitoring.
  • A significant association was observed between toxicity levels and T cell signatures with distinct genetic expressions linked to poor outcomes with cilta-cel treatment.
  • Analysis included single-cell RNA sequencing from 59 patients across various CAR T cell therapies, highlighting unique CAR T cell behavior in response to treatments.
  • Findings suggest neurotoxic risks in treatment protocols, implying the need for enhanced detection strategies and strategies to optimize CAR T cell functionality.

Cite This Study

Parker et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e501https://doi.org/10.1182/blood-2025-503
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma2025
  2. 2The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma2025 · 1 citations
  3. 3Longitudinal immune monitoring in patients treated with CD19 and BCMA CAR-T cells using standardized 8‑color flow cytometry panel reveals substantial differences among products kinetics and persistence2025 · 1 citations
  4. 4Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality2025 · 7 citations
  5. 5Assessment of long-term persistence and phenotypic features of BCMA CAR-T cells in patients with relapsed or refractory multiple myeloma treated with ciltacabtagene autoleucel.2026